Mycobacterial infections in solid organ transplant recipients

Mycobacterial infections represent a growing challenge for solid organ transplant recipients (SOT). The adverse effects of tuberculosis (TB) therapy present a major difficulty, due to the interactions with immunosuppressive drugs and direct drug toxicity. While TB may be donor-transmitted or communi...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical microbiology and infection Vol. 20; no. s7; pp. 89 - 101
Main Authors:	Meije, Y., Piersimoni, C., Torre-Cisneros, J., Dilektasli, A.G, Aguado, J.M
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-09-2014 Elsevier Limited
Subjects:	Antitubercular Agents - therapeutic use Drug Interactions Drug Resistance, Bacterial Drug Therapy - methods Humans Immunocompromised Host Immunosuppressive Agents - therapeutic use Infections Latent tuberculosis infection mycobacteria Mycobacterium non-tuberculous mycobacteria Opportunistic Infections - diagnosis Opportunistic Infections - epidemiology Opportunistic Infections - prevention & control Opportunistic Infections - therapy Organ Transplantation solid organ transplantation Transplant Recipients Transplants & implants Tuberculosis Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis - epidemiology Tuberculosis - prevention & control non-tuberculous mycobacteria solid organ transplantation Latent tuberculosis infection mycobacteria tuberculosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Mycobacterial infections represent a growing challenge for solid organ transplant recipients (SOT). The adverse effects of tuberculosis (TB) therapy present a major difficulty, due to the interactions with immunosuppressive drugs and direct drug toxicity. While TB may be donor-transmitted or community-acquired, it usually develops at a latent infection site in the recipient. Pre-transplant prevention efforts will improve transplant outcomes and avoid the complications associated with post-transplant diagnosis and treatment. The present review and consensus manuscript is based on the updated published information and expert recommendations. The current data about epidemiology, diagnosis, new regimens for the treatment of latent TB infection (LTBI), the experience with rifamycins for the treatment of active TB in the post-transplant period and the experience with isoniazid for LTBI in the liver transplant population, are also reviewed. We attempt to provide useful recommendations for each transplant period and problem concerning mycobacterial infections in SOT recipients.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	1198-743X 1469-0691
DOI:	10.1111/1469-0691.12641